US Patent 9,731,082: Claim Scope, Patent Landscape, Exclusivity, and Generic-Entry Risk
US Patent 9,731,082 protects a preassembled injection-device package in which a threaded adaptor is friction-mounted on a container tip and immobilized by a heat-shrinkable film. The core commercial value is the combination of mechanical adaptor retention, unobstructed access to the adaptor’s internal thread, and tamper-evident or labeling functions provided by the shrink film. The claims cover both the assembly and its manufacturing method, but they do not claim a drug, active pharmaceutical ingredient, therapeutic indication, or drug formulation.
What does US Patent 9,731,082 claim?
Claim 1 is the principal apparatus claim. It requires every element below:
| Claim limitation |
Scope and technical significance |
| Injection device |
The claimed product must include an injection device, not merely a standalone adaptor or package |
| Container |
The device must have a container for a product |
| Distal tip and channel |
The container tip must include a channel through which the product passes |
| Adaptor ring |
The adaptor must include a ring mounted on the distal tip |
| Internal thread |
The ring must have an internally threaded portion |
| Radially inward projection |
The ring must include an inner projection extending radially inward |
| Friction mounting |
The adaptor must be held on the distal tip through friction between the projection and the tip |
| Tip extension |
The distal tip must extend into the internally threaded portion |
| Distal-end relationship |
The distal end of the tip must extend beyond the adaptor’s distal end |
| Heat-shrinkable film |
Film must cover at least part of both the container and adaptor |
| Uncovered ring end |
The film cannot cover the distal end of the ring, preserving access to the internal thread |
| Immobilization |
In the heat-shrunk condition, the film must block adaptor rotation and translation relative to the container |
The claim is narrow in architecture but potentially meaningful in practice. A competing product can avoid infringement by removing any one required limitation, such as the inward projection, the friction fit, the exposed distal ring end, or the film’s function of blocking both rotation and translation.
How strong is the independent apparatus claim?
Claim 1 has substantial structural specificity. It does not merely claim a syringe with a shrink sleeve. It requires a particular relationship among the container tip, threaded adaptor, friction projection, and film.
The strongest limitations are:
- The adaptor ring must be friction-mounted through an inward radial projection.
- The container tip must pass into the threaded portion and project beyond the adaptor.
- The heat-shrinkable film must cover both the container and adaptor.
- The film must leave the distal ring end exposed.
- The shrunk film must immobilize the adaptor in both rotation and translation.
These limitations create multiple potential noninfringement positions. A product using a snap-fit collar, adhesive-only attachment, external threads, a separate locking clip, or a sleeve that covers the entire threaded ring may fall outside the literal scope of claim 1.
The claim also requires the film to perform a functional role. A film that merely provides labeling or tamper evidence but does not maintain the adaptor blocked in rotation and translation may not satisfy the claim.
What do dependent claims 2 through 13 protect?
The dependent claims narrow the assembly by adding film materials, labels, plugs, break lines, adhesive, writing, and medical-fluid use.
| Claim |
Additional limitation |
Commercial relevance |
| 2 |
Film made from PVC, PET, OPS, OPP, PLA, or mixtures |
Limits the material class while identifying common shrink-film materials |
| 3 |
Film is PVC |
Particularly relevant to PVC shrink sleeves |
| 4 |
Label imprisoned between film and both container and adaptor |
Protects an internal label arrangement |
| 5 |
Label located on the exterior of the film |
Covers conventional sleeve labeling |
| 6 |
Plug mounted on adaptor |
Extends protection to capped or plugged assemblies |
| 7 |
Film also covers part of the plug |
Adds sleeve coverage over the closure |
| 8 |
Annular breakable line over part of the plug |
Supports tamper-evident opening |
| 9 |
Film is at least partly glued to container or adaptor |
Covers shrink film combined with adhesive |
| 10 |
Film contains writing |
Covers printed film |
| 11 |
Label imprisoned between film and container |
Narrower label location |
| 12 |
Label imprisoned between film and adaptor |
Narrower label location |
| 13 |
Product is a medical fluid |
Connects the assembly to medical-use products |
Claims 4, 11, and 12 are not interchangeable. Claim 4 requires a label between the film and both the container and adaptor. Claims 11 and 12 separately address a label positioned against the container or adaptor.
Claim 13 does not require a drug or a particular therapeutic use. “Medical fluid” can encompass products such as injectable solutions, contrast media, flushing solutions, biologic preparations, or other fluids used in medical delivery systems, subject to the ordinary meaning applied in the patent record.
What does method claim 14 cover?
Claim 14 is a manufacturing-process claim corresponding to claim 1. It requires:
- Providing the injection device and container.
- Providing an adaptor with an internally threaded ring and inward projection.
- Fitting the adaptor onto the distal tip by friction.
- Positioning the tip so that it extends beyond the adaptor’s distal end.
- Bonding heat-shrinkable film over part of the adaptor and container.
- Leaving the distal ring end uncovered.
- Heating the film until it shrinks tightly.
- Achieving adaptor immobilization in rotation and translation.
The process claim is important because it can reach manufacturing conduct even where the final product is imported or sold by a different entity. Its practical value depends on where assembly and heat-shrink operations occur, the availability of process evidence, and whether the accused product was made using the claimed sequence.
A manufacturer may reduce method-claim exposure by using a different adaptor-retention mechanism, applying a preformed sleeve rather than bonding and shrinking film in the claimed manner, or securing the adaptor after shrink processing.
What do method claims 15 through 18 add?
| Claim |
Additional manufacturing limitation |
| 15 |
Plug is mounted on the adaptor and the film covers part of the plug |
| 16 |
Breakable line is designed before the film is bonded to the assembly |
| 17 |
Film is a rectangular sheet when bonded |
| 18 |
Product is a medical fluid |
Claim 17 may be relevant to manufacturing-line design. A preformed tubular sleeve, rather than a rectangular sheet, could provide a possible design-around if all other claim limitations are also avoided. The claim does not, however, necessarily exclude every sleeve that begins as a flat web and is formed during processing. Claim construction would control.
What patents protect the injection-device adaptor and shrink-film concept?
US 9,731,082 protects a combination technology rather than a pharmaceutical compound. The relevant patent landscape has four technical clusters:
Friction-mounted threaded adaptors
This cluster includes collars or rings secured to syringe or cartridge tips through radial interference, projections, ribs, or other frictional structures. Key freedom-to-operate questions include whether the competing adaptor has:
- An internally threaded ring;
- A discrete inward projection;
- Contact friction between that projection and the container tip;
- A tip extending beyond the adaptor;
- A threaded interface accessible at the distal end.
A product with a conventional luer-lock structure may overlap functionally but avoid the specific radial-projection architecture.
Shrink-film immobilization systems
This cluster covers sleeves or films that stabilize a removable adaptor against axial movement or rotation. The distinguishing issue is whether the film merely surrounds the components or mechanically blocks both forms of movement after heat shrinking.
Shrink film applied only over the container may not satisfy claim 1. A film covering the adaptor but extending over the distal end of the threaded ring may also present a limitation dispute.
Tamper-evident plug and break-line systems
Claims 6 through 8 and 15 through 16 address a plug covered by shrink film with an annular breakable line. The relevant competing rights may concern:
- Breakable bands;
- Perforated or scored sleeves;
- Tear strips;
- Frangible caps;
- Tamper-evident seals positioned over threaded adaptors.
These features may be covered by separate packaging patents even when the underlying adaptor falls outside claim 1.
Labels and printed shrink sleeves
Claims 4, 5, and 11 through 12 cover labels either imprisoned beneath the film or placed on the film. Separate rights may exist for label placement, serialization, anti-counterfeit features, or inspection systems. Those rights are technically adjacent but do not necessarily overlap the core adaptor claim.
Is US 9,731,082 a drug patent or an Orange Book patent?
No. The claims are directed to a device assembly and its manufacturing method. They do not claim:
- An active ingredient;
- A pharmaceutical composition;
- A dosage regimen;
- A disease-treatment method;
- A drug formulation;
- A biologic;
- A drug substance manufacturing process.
The FDA Orange Book lists patents submitted for approved drug products under the Hatch-Waxman framework. A device patent of this type is not ordinarily an Orange Book-listed patent merely because the device delivers a medical fluid. The patent therefore does not create a conventional Paragraph IV challenge pathway against an approved drug product. FDA regulatory exclusivity and patent protection should be analyzed separately. [2]
If the assembly is marketed as part of a combination product, the patent may affect the device component, packaging, or delivery system. That does not convert the patent into a drug patent or create standalone pharmaceutical exclusivity.
When does US 9,731,082 lose exclusivity?
A US utility patent generally expires 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments. The issue date, September 2017, does not determine the expiration date. [3]
The patent’s enforceability also depends on:
- Payment of maintenance fees;
- Any terminal disclaimer;
- Patent-term adjustment;
- Reexamination or post-grant proceedings;
- Claim amendments or cancellations;
- Court judgments;
- Disclaimer or expiration events.
The claims supplied do not establish the patent’s filing date, maintenance-fee history, terminal disclaimer status, or final term calculation. Those matters are recorded in the USPTO patent file and official patent-term records. [1]
Because the patent is a device patent, there is no FDA five-year new chemical entity exclusivity, three-year clinical-investigation exclusivity, seven-year orphan-drug exclusivity, or twelve-year reference-biologic exclusivity attached to these claims.
Are there Paragraph IV challenges or generic-entry risks?
A Paragraph IV certification is not the normal challenge mechanism for this patent because the claims do not protect an FDA-approved drug product or active pharmaceutical ingredient. Generic-drug applicants could still face commercial or supply-chain risk if their prefilled syringe, cartridge, vial adaptor, or tamper-evident package practices the claims.
The principal entry risks are:
| Entry scenario |
Risk under US 9,731,082 |
| Same friction-fit threaded adaptor and shrink film |
High, if every claim 1 limitation is present |
| Same adaptor but no shrink film |
Lower under the apparatus claim |
| Shrink film covers only the container |
Lower if it does not immobilize the adaptor |
| Adhesive-mounted adaptor without inward projection |
Potential design-around |
| Snap-fit adaptor with no frictional projection |
Potential design-around |
| Film covers distal ring end |
Potential limitation to claim 1 |
| Product uses an unthreaded adaptor |
Likely outside the literal claim |
| Process uses a tubular sleeve rather than a bonded rectangular sheet |
Requires claim-by-claim process analysis |
| Product is not a medical fluid |
May avoid only claims 13 and 18, not claim 1 or 14 |
A product can infringe claim 1 even if it avoids claims 2 through 13. The dependent claims do not define the full scope of the patent.
What manufacturing and intellectual-property barriers matter?
The patent’s commercial barrier is concentrated in packaging and assembly integration. A manufacturer must coordinate:
- Tip and adaptor tolerances;
- Frictional retention force;
- Thread accessibility;
- Film shrink ratio;
- Heat exposure to the container and product;
- Compatibility with sterile manufacturing;
- Label placement;
- Plug retention;
- Tamper-evident opening;
- Inspection of sleeve coverage and break lines.
The claims do not expressly require a sterile product, a syringe, a cartridge, a particular polymer grade, or a specific heating temperature. Those omissions may broaden the technical field beyond a single commercial presentation.
At the same time, the claim requires a precise spatial arrangement. Variations in ring geometry, film endpoint, or adaptor retention can materially affect infringement analysis.
What patent litigation, licensing deals, or settlements affect the patent?
The claim text identifies no litigation, licensing arrangement, settlement, or covenant not to sue. Such commercial events do not appear from the claims themselves and would not change the meaning of the issued claim language unless reflected in a court judgment, prosecution record, disclaimer, or claim amendment.
The absence of a drug claim also means that conventional branded-drug settlement analysis is not the primary framework. Any dispute would more likely involve medical-device manufacturers, syringe or cartridge suppliers, contract manufacturers, packaging companies, or combination-product sponsors.
How does this patent compare with conventional luer-lock and tamper-evident systems?
| Technology |
Key difference from US 9,731,082 |
| Conventional integrated luer-lock syringe |
May lack a separately friction-mounted adaptor and shrink-film immobilization |
| Snap-on needle adaptor |
May lack the claimed inward projection and threaded-ring geometry |
| Adhesive-bonded collar |
May avoid the required friction mounting |
| Shrink sleeve over a cap |
May not cover both container and adaptor or block adaptor movement |
| Tear-strip tamper seal |
May lack heat-shrinkable film and the claimed adaptor structure |
| Preformed plastic overcap |
May avoid the rectangular-sheet manufacturing limitation in claim 17 |
| Threaded adaptor with no projecting tip |
May avoid the distal-tip relationship in claim 1 |
This comparison is structural, not a legal infringement conclusion. Claim construction and the accused product’s actual dimensions and assembly method remain decisive.
Key Takeaways
- US 9,731,082 is a medical-device and packaging patent, not a conventional drug patent.
- Claim 1 requires a specific friction-mounted, internally threaded adaptor and a heat-shrunk film that blocks rotation and translation.
- The film must cover part of both the container and adaptor while leaving the distal ring end accessible.
- Claims 2 through 13 add polymer materials, labels, plugs, break lines, adhesive, writing, and medical-fluid use.
- Claim 14 separately protects the manufacturing sequence.
- The patent does not create Orange Book listing rights, FDA drug exclusivity, or a standard Paragraph IV pathway.
- The main design-around options involve changing adaptor retention, eliminating the shrink film, altering film coverage, removing the internal thread, or changing the manufacturing process.
- Patent expiration cannot be calculated from the issue number alone. The controlling term depends on the earliest effective filing date and any term adjustments or disclaimers.
- Commercial exposure is concentrated in prefilled injection devices, cartridge systems, threaded adaptors, tamper-evident closures, and shrink-sleeve packaging.
FAQs About US Patent 9,731,082
Does US 9,731,082 cover a syringe itself?
No. It covers an assembly containing an injection device, adaptor, and heat-shrinkable film. A syringe lacking the claimed adaptor and film arrangement would not satisfy claim 1.
Can a product infringe if its shrink film is made from PET instead of PVC?
Yes. Claim 2 expressly includes PET, and claim 1 is not limited to a particular film material. PVC is only the narrower subject of claim 3.
Does a luer-lock connection automatically infringe this patent?
No. A luer-lock product must still satisfy the inward-projection friction mount, distal-tip extension, exposed ring end, shrink-film coverage, and immobilization limitations.
Does claim 13 cover every injectable drug?
No. Claim 13 depends on claim 1 and requires the product to comprise a medical fluid. It does not independently claim every injectable drug and does not claim an active ingredient.
Can changing the sleeve from a rectangular sheet avoid the patent?
It may avoid claim 17, but not necessarily claim 14 or claim 1. The broader claims do not expressly require a rectangular sheet.
References
-
United States Patent and Trademark Office. (n.d.). US Patent No. 9,731,082, patent file and status records. USPTO Patent Center.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
-
35 U.S.C. §§ 154, 156. (2024). Term of patent; extension of patent term. United States Code.
